Inoviq Ltd · ASX:IIQ
Inoviq — BARD1 Life Sciences — Investor Presentation (November 2018)
23 slides from Inoviq's investor presentation, Nov 19, 2018
Slide 1: Early cancer detection to save lives
Early cancer detection to save lives COMPANY PRESENTATION 19 November 2018
Slide 2: Disclaimer
2 DISCLAIMER This presentation has been prepared by BARD1 Life Sciences Limited (“BARD1” or the “Company”) based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of
Slide 3: BARD1 Life Sciences
3 BARD1 Life Sciences Medtech company focused on developing and commercialising non-invasive diagnostics for early detection of cancer to save lives FINANCIAL INFORMATION TOP SHAREHOLDERS (16/11/18) # SHARES % HOLDING Ticker ASX:BD1 Irmgard Irminger-Finger 108,252,420 13.06% Share Price (@16/11/18)
Slide 4: Investment Highlights
4 Investment Highlights ■ Medtech company focused on developing non-invasive diagnostics for early detection of cancer to save lives ■ Proprietary tumour marker platform with strong IP protecting biomarkers, methods and use ■ Targeting unmet needs in burgeoning US$101B global cancer diagnostics mark
Slide 5: Behind BARD1's diagnostic success
5 Behind BARD1’s diagnostic success ■ Proprietary tumour marker platform and diagnostic approach Autoantibodies enable early ■ BARD1 blood tests measure detection of cancers across all autoantibodies to BARD1 proteins and stages before symptoms appear use an algorithm to give a cancer score Physicia
Slide 6: Proprietary BARD1 tumour marker platform
6 Proprietary BARD1 tumour marker platform ■ Normal cells express BARD1 protein (FL) that functions as a tumour suppressor to prevent cancer ■ Cancer cells express variant BARD1 isoforms that drive tumour formation and are correlated with cancer progression and poor prognosis ■ BARD1 isoforms are im
Slide 7: Focused on unmet needs in Global Cancer Diagnostics Market of US$101b
7 Focused on unmet needs in Global Cancer Diagnostics Market of US$101b1 $7b Ovarian Ca Global market $26b Lung Ca $20b Breast Ca US market opportunities for screening tests2 Breast & Ovarian Cancer Lung Cancer 48.4m average-risk 6.8m eligible current or women 50-74 years3 former smokers 55-77y4 Ann
Slide 8: Breast Cancer is the biggest cancer killer of women
8 Breast Cancer is the biggest cancer killer of women ■ Breast Cancer is the most common cancer in women worldwide Breast Cancer 5-Year Survival Rates □ World: 2.1m new cases & 627k deaths pa □ US: 266k new cases & 41k deaths pa Overall 90% ■ Risk factors include age >55 years (69%), family history
Slide 9: BARD1-Breast a world-first solution
9 BARD1-Breast a world-first solution Blood test in development for early detection of breast cancer ■ Measures BARD1 autoantibodies in the blood to give a breast cancer score ■ Breakthrough case-control study in 174 samples shows 86% accurate for early detection of breast cancer in women across com
Slide 10: Ovarian Cancer continues to devastate
10 Ovarian Cancer continues to devastate ■ Ovarian Cancer is the leading cause of Ovarian Cancer* 5-Year Survival Rates gynecological cancer deaths □ World: 295k new cases & 185k deaths pa Overall 47% □ US: 22k new cases & 14k deaths pa ■ Risk factors include age >55 years (70%), family history (<10
Slide 11: BARD1-Ovarian changes the landscape
11 BARD1-Ovarian changes the landscape Blood test in development for early detection of ovarian cancer ■ Measures BARD1 autoantibodies and CA125 in the blood to give an ovarian cancer score ■ 7 case-control studies in 743 samples show excellent diagnostic accuracy of AUC 0.95 for early detection of
Slide 12: Lung Cancer remains the biggest cancer killer
12 Lung Cancer remains the biggest cancer killer ■ Lung Cancer is the leading cause of cancer Lung Cancer 5-Year Survival Rates deaths worldwide □ World: 2.1m new cases & 1.8m deaths pa Overall 19% □ US: 234k new cases & 154k deaths pa ■ Risk factors include age >55 years (91%) Stage 1A3 77% and smo
Slide 13: BARD1-Lung test
13 BARD1-Lung test Blood test in development for early detection of lung cancer ■ Measures BARD1 autoantibodies in the blood to give a lung cancer score ■ 2 case-control studies in 628 samples shows high accuracy for early detection of lung cancer with up to 80% sensitivity and 77% specificity, and
Slide 14: BARD1-Vaccine
14 BARD1-Vaccine Exploratory research program for a potential cancer vaccine ■ OBJECTIVE: POC study to evaluate BARD1 peptide vaccine formulations for cancer prevention and/or treatment in murine cancer models to assess in vivo effectiveness for reducing tumour size, inhibiting tumour growth and/or
Slide 15: BARD1 Key Milestones
15 BARD1 Key Milestones 2018 2019 2020 2021 CY Q3 Q4 Q1 Q2 Q3 Q4 Assay Dev Clinical Validation Ovarian Launch Assay Dev Clinical Validation Breast Launch Assay Dev Lung R&D to advance other Dx for early cancer detection Research IRH cancer vaccine research BD and partnerships Commercial New patents
Slide 16: Commercialisation Strategy
16 Commercialisation Strategy Assay Marketing/ Research Clinical Validation Development Approval ✓POC studies ✓Product • Clinical testing • Product launch of completed validating development planned for 2H19 to BARD1-Breast/ biomarker platform in underway to demonstrate clinical Ovarian anticipated
Slide 17: BARD1's Intellectual Property Portfolio
17 BARD1’s Intellectual Property Portfolio ■ 5 patent families covering various BARD1 DNA & protein sequences, methods of diagnosis & treatment, and use in multiple cancers Patent Family Title Granted Pending Expiry 5 10 19 PCT/FR01/02731 Truncated BARD1 protein and its US, JP 2021 diagnostic and th
Slide 18: Significant Achievements 2018
18 Significant Achievements 2018 Date Announcements ✓ OC-400 results showing 82% sensitivity and 79% specificity for detection of ovarian 9/1/18 cancer 2/2/18 ✓ JP Divisional Patent granted providing broader protection for lung & colorectal cancer 6/3/18 ✓ OC-400V results showing 89% sensitivity and
Slide 19: Expected news flow in next 12 months
19 Expected news flow in next 12 months • Complete Assay Development and technical validation on Luminex® BARD1- instrumentation – 1Q19 Ovarian • Commence clinical studies for BARD1-Breast and BARD1-Ovarian for early detection of breast and ovarian cancers – 2H19 ✓Results from research studies for o
Slide 20: Peer Valuations | BD1 has significant growth potential
20 Peer Valuations| BD1 has significant growth potential NASDAQ:VRML US$37.7m AIM:ONC £59.5 FDA-cleared IVDs OVA1® & Marketed LDT 2009 & CE-IVD Overa® for risk assessment of 2017 EarlyCDT®-Lung with 41% ovarian cancer with up to 92% sens & 93% spec. Jan-18 license sens & 69% spec. with Genostics for
Slide 21: Leadership Team
21 Leadership Team PETER GUNZBURG BCom | Chairman Public company director, stockbroker & technology investor, with 20+ years corporate advisory, capital raising, transaction & business management experience. Currently Chair of the Institute for Respiratory Health at UWA. Previously Director of Resol
Slide 22: Investment Summary
22 Investment Summary Early cancer diagnostics targeting unmet needs in US$101B global Large Markets market Industry leading results for BARD1-Breast & BARD1-Ovarian for early Compelling Results detection of breast & ovarian cancers with high sensitivity & specificity BARD1-Ovarian development & val
Slide 23: Contacts
23 Contacts BARD1 Life Sciences Ltd Ground, Tempo Building, 431 Roberts Rd Subiaco WA 6008 Australia P +61 8 9381 9550 | E [email protected] | W www.bard1.com Dr Leearne Hinch | CEO Peter Gunzburg | Chairman E [email protected] E [email protected] M 0400414418
BARD1 Life Sciences — Investor Presentation (November 2018) on 6ix